What were the key drivers of Johnson & Johnson's sales growth in Q1 2003?

Sales growth was driven by strong performance across all three segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics. Favorable currency exchange rates also contributed significantly, particularly for international sales. Specific product drivers included strong performance in skincare and sweetener products in the Consumer segment, key pharmaceuticals like REMICADE and RISPERDAL, and growth in orthopaedics and surgical products within Medical Devices & Diagnostics.

How did the company's profitability change in the first quarter of 2003?

Profitability improved significantly. Net earnings increased by 12.9% to $2.1 billion, and diluted earnings per share grew by 16.9% to $0.69. This was supported by a 0.4% increase in gross profit margin to 72.3%, attributed to effective cost control measures, and a slight increase in earnings before taxes on income, which grew 11.8%.

What significant acquisitions or business development activities occurred or were announced during the quarter?

Johnson & Johnson completed the acquisition of Scios Inc., a biopharmaceutical company focused on cardiovascular and autoimmune diseases, for approximately $2.4 billion. They also announced definitive agreements to acquire Link Spine Group, Inc., for spine disorders, and completed smaller acquisitions like Orquest, Inc., Orapharma, Inc., and 3-Dimensional Pharmaceuticals, Inc., which bolstered their offerings in orthopaedics, pharmaceuticals, and drug discovery.

Are there any significant legal proceedings that investors should be aware of?

The company is involved in numerous legal proceedings, most notably a significant number of lawsuits related to the drug PROPULSIDr, which was withdrawn from the market. While the company is defending these claims vigorously, they acknowledge the potential for significant impact on future earnings, though they believe their insurance and reserves are adequate. Additionally, there are ongoing patent infringement cases related to their stent products and generic drug challenges, as well as investigations into the marketing practices for sutures and endoscopic instruments.

JNJ 10-Q Quarterly Report Q1 FY2003 — Revenue, Net Income, EPS

Summary

Johnson & Johnson reported a strong first quarter for 2003, demonstrating robust top-line growth and improved profitability. Worldwide sales increased by 12.3% to $9.8 billion, driven by broad-based strength across its Consumer, Pharmaceutical, and Medical Devices & Diagnostics segments. This growth was supported by favorable currency movements and solid operational performance in key product areas. The company also saw an improvement in its gross profit margin, reflecting effective cost control measures. Net earnings rose by 12.9% to $2.1 billion, translating to a 16.9% increase in diluted earnings per share to $0.69. The company continued its strategic acquisitions, notably the completed acquisition of Scios Inc. and the agreement to acquire Link Spine Group, Inc., which are expected to bolster its pipeline in key therapeutic areas. J&J also announced a significant increase in its quarterly dividend, highlighting its commitment to returning value to shareholders and its confidence in future performance.

Key Highlights

1Worldwide sales increased 12.3% to $9.8 billion compared to the prior year's first quarter.
2Net earnings grew 12.9% to $2.1 billion, with diluted EPS rising 16.9% to $0.69.
3Gross profit margin improved to 72.3% from 71.9% in the prior year's quarter.
4Strategic acquisitions, including Scios Inc. and planned acquisition of Link Spine Group, Inc., were announced/completed, enhancing the product portfolio.
5The company increased its regular quarterly cash dividend by 17.1% to $0.24 per share.
6Pharmaceutical segment sales showed strong performance driven by key products like REMICADE, RISPERDAL, and DURAGESIC.
7Medical Devices & Diagnostics segment sales grew 13.7%, despite a decline in U.S. Cordis stent sales in anticipation of the CYPHER stent launch.

JOHNSON & JOHNSON Quarterly Report for Q1 Ended Mar 30, 2003

Summary

Key Highlights

Frequently Asked Questions